
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is poised for potential success with their lead drug, OST-HER2, which has shown promise in preventing or delaying recurrence in osteosarcoma patients. The company has multiple upcoming catalysts, such as data updates, regulatory meetings, and potential approval decisions, which could provide significant financial opportunities. Additionally, the company has received orphan, fast track, and rare pediatric disease designations, which could expedite development and review. With a planned global Phase 3 trial and potential monetization of a Priority Review Voucher, OS Therapies has a positive outlook for the future.
Bears say
OS Therapies is facing multiple risks that could impact their future success, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. Additionally, despite their coordinated regulatory engagement and potential for an accelerated approval pathway, the company's Phase 3 trial for OST-HER2 in metastatic osteosarcoma will not take place until Q3 2026, leading to a potential market entry in the second half of that year. These factors contribute to a negative outlook on the stock's future performance and growth potential.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares